This week’s biotechnology news headlines include, zika virus news, CellMedica links with UCL in research deal, FDA approves Novartis biosimilar to Amgen’s Enbrel, Biogen gains fast-track Alzheimer’s drug review in wake of early data, Sunovion pays $624M for Canada’s Cynapsus lead PhIII Parkinson’s med, and Takeda to develop Zika vaccine in Mass.
Cell Culture Events
VISION leadership course is uniquely tailored for the bioindustry to capture the synergies between bioscience, technology and business practice – Keck Graduate Institute, Claremont, CA – September 14-16, 2016
UCL Biochemical Engineering in collaboration with Keck Graduate Institute is announcing its 2016 VISION Leadership Programme. Designed for talented high impact individuals, VISION provides executive leadership insights tailored for present & future leaders in the bioindustries through rigorous intellectual analysis & intensive, practical, peer-to-peer action-based learning giving you the tools required to drive innovation, entrepreneurship & global leadership in your organisation.
KEY BENEFITS AND IMPACT:
Know how to make the transition from science & engineering based decision making towards company- wide strategic resolutions
Build an invaluable network with elite peers & experts from academia & industry who challenge, stimulate & inspire you
Gain perspectives on leadership challenges & critical business issues facing the bioindustry globally & formulate actions to address these
Learn from real life cases studies to succeed in making difficult decisions & implementing strategies to secure a more robust future for your business
Access & share best practices on how to be a good leader & avoid pitfalls in constantly evolving market
Achieve your personal development & career objectives
Evaluate the impact of key innovative research & technologies on the future of business & manufacturing
CONFIRMED SPEAKERS FOR 2016
Barry Buckland, CEO, BiologicB
Charles Cooney, Professor, MIT
Nigel Darby, former VP, GE Healthcare
Parrish Galliher, CTO, GE Healthcare
Phil Gomez, Principal, PricewaterhouseCoopers
Ljiljana Minwalla, Senior Legal & Patent Counsel, Mesoblast, Inc.
Andrew Ramelmeier, Senior VP, Portola Pharmaceuticals
Rahul Singhvi, COO, Takeda Vaccines
WHO SHOULD ATTEND
Managers & practitioners fast tracked for executive roles or intending to move into leadership positions
Current executives intending to interact with fellow leaders & expert speakers to debate & exchange novel thoughts & opinions
Funding agencies wanting to interact with present & future thought leaders to gain insights into the sector trends & skills required to navigate the changing bioindustry landscape
VISION combines innovative management thinking with cutting edge research to ensure high flyers perform optimallyFor more information contact firstname.lastname@example.org and visit www.ucl.ac.uk/biochemeng/visionprogramme
Date: Thursday, September 22, 2016
Time: 02:30 PM Eastern Daylight Time
Duration: 1 hour, 30 minutes
Exosomes encapsulate and transport a wide variety of molecules generated by their cell-of-origin, a process now thought to be a form of cellular signaling. Exosome signaling is common across cell types and species, but it is of particular interest in diseases with an inflammatory component. While exosome isolation and analysis is useful to understanding the mechanisms behind these multifaceted diseases, exosomes may also be exploited for their therapeutic potential. The Scientist is bringing together a panel of experts to review the current knowledge on exosomes in inflammation, and to explore the potential for exosome-based therapeutics. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.
Topics to be covered:
The exosomal cargoes released during inflammation, and their potential as therapeutic targets
How inflammatory diseases are uniquely suited to exosome analysis
The biopharmaceutical industry has developed into a multi-billion dollar market in just 30 years. Making decisions and setting up strategies in a rapidly changing environment can be challenging. The difference between a good and a great decision can have extensive implications for the future of a company. In this environment, knowledge and experience are what make the difference. Good insights about, for example, technical advancements, process economy implications, and sustainability aspects can help improve the individual decisions and strengthen the overall business strategy.
In this webinar series, four renowned subject matter experts will share their insights into four areas of bioprocessing: upstream, vaccines, downstream, and single-use technology. We will present tangible, recently developed data that can help you in developing modern, cost-efficient, and sustainable bioprocesses.
Don’t miss these on demand webinars – http://www.bioprocessintl.com/sponsored-content/bioprocess-insights-webinars/
BioAnalytical and Formulaiton Summit – September 14-15, 2016 – Berlin, Germany https://lifesciences.knect365.com/bioanalyticalandformulation The Bioanalytical & Formulation Summit provides the ultimate opportunity to discuss your current challenges in analytical methods for biologics, with 2 streams dedicated to:
Protein Characterisation and Post Translational Modifications
Formulation for Biologics
Join your peers for expert insight, new data, and the latest technology updates for formulation and QC strategies, to inform your methods and improve your product quality and efficacy.
CAR-TCR Summit – September 13-16, 2016 – Boston, MA – http://car-tcr-summit.com/ If you are attending the CAR-TCR Summit, please stop by Roche Custom Biotech at booth 33 to see their showcased products and capabilities:
Cedex HiRes automated cell counter
Cedex Bio and Bio HT nutrient/metabolite analyzers
2nd Annual Cell & Gene Therapy Congress – November 3-4, 2016 – London, UK – http://www.celltherapy-congress.com/Over 250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions.Over 20 presentations and case studies focused on the key issues in cell & Gene Therapy development, updates in regulatory pathways, commercialisation, bioprocessing and manufacturing2 interactive streams:Cell & Gene Therapy: Development, Clinical Trials & Commercialisation
Cell Therapy Bioprocessing and Manufacturing
Co-located with the established 5th Annual Cell Culture & Bioprocessing Congress and 3rd Annual Stem Cell CongressFree Pre-Congress WebinarAdvances In Gene Editing Technologies
Presented by Richard Morgan, Vice President, Immunotherapy at Bluebird Bio. – Register for free today >>
5th Annual Cell Culture & Bioprocessing Congress – November 3-4, 2016 – London, UK – http://www.cellculture-congress.com/Over 170 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions50 presentations, case studies and panel discussions focused on the key issues in cell line optimisation, process development and biological production4 interactive streams:Early Cell Line Development
Late Stage Cell Line Development
14 pre-scheduled one to one meetings, exhibition and informal networking opportunitiesCo-located with our 3rd Annual Stem Cell Congress and our 2nd Annual Cell & Gene Therapy Congress
TIDES Europe – November 14-17, 2016 – Berlin, Germany – http://get.knect365.com/tides-europe/TIDES Europe is the place where oligo and peptide experts go to meet and build successful partnerships to accelerate products from early discovery through late stage development and commercialisation. In 2015 Tides Europe attracted a 40% increase in attendance across the oligo and peptide audience.
World Precision Medicine – November 14-15, 2016 – Washington DC
The World Precision Medicine Congress USA is bringing together big pharma, big data, and healthcare providers to discuss the scientific, economic, and policy goals towards producing precise and genomic-based medicines. Partnered with forward-looking industry leaders such as precisionFDA and NantWorks, this event will fast-track our momentum into the future paradigm of healthcare by spurring the important discussions to get us there.
Can you afford to miss this gathering of precision medicine leaders? Pharma, big data, and healthcare providers will be there attending sessions on Gene Therapy, Cell Therapy, personalized medicine, and genomics.
Download the brochure: http://bit.ly/1N3Y0vI
Register to attend: http://bit.ly/1ObpkNV
“Exactly 100 years ago this summer, New York City was hit by one of the worst epidemics it had ever seen: the first explosive American outbreak of infantile paralysis — a disease later known as polio. It was a mystifying, terrifying illness. Most victims were toddlers. Initially, they didn’t even look terribly ill; often, they woke up feverish and cranky, saying their necks hurt.”
If you like this story, please see our blog titled “Cell Therapy for Parkinson’s Disease – An update on the move toward clinical trials”
“The U.S. Food and Drug Administration on Tuesday approved Novartis AG’s biosimilar version of Amgen Inc’s arthritis drug Enbrel. The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition.”
If you like this story, please see our blog titled “Ten Years of Induced Pluripotent Stem Cells: A Look Back”
“Sunovion Pharmaceuticals is to pay a 120% premium to buy out Canadian biotech Cynapsus Therapeutics as it looks to get its hands on the company’s late-stage Parkinson’s disease candidate. Cynapsus ($CYNA) closed before the deal was announced at just over $18 a share, with Sunovion putting $40.50 a share, or $624 million, down for the drugmaker–a 120% premium over its closing price.”
If you like this story, please see our blog titled “Gene Therapy Strengthened by Recent Successes”
“Takeda Pharmaceutical Co. is joining the campaign to develop a Zika vaccine with nearly $20 million in US funding for a Cambridge-based research program. The company, which last year said it will move its global vaccines business to Cambridge from Deerfield, Ill., disclosed Thursday that it was tapped by the Biomedical Advanced Research and Development Authority to produce a vaccine to treat the virus in the United States and abroad.”
If you like this story, please see our blog titled “Real Time IgG Titer Measurement Enables PAT (Process Analytical Technology) Implementation”